Century Therapeutics, Inc. (IPSC)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USDTTM unavailable| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 0 | 0 | 5 | 2 | 7 | 109 | - | - |
| Operating profit | $m | -15 | - | ||||||
| Net profit | $m | -54 | -96 | -131 | -137 | -127 | -10 | - | -45 |
| EPS reported | $ | -0.11 | - | ||||||
| Operating cashflow per share | $ | -1.20 | - | ||||||
| Capex per share | $ | 0.01 | - | ||||||
| FCF per share | $ | -1.21 | - | ||||||
| Free cash flow | $m | -105 | - | ||||||
| Net debt | $m | -117 | - | ||||||
| Book value equity | $m | 159 | - | ||||||
| Book value per share | $ | 1.84 | - | ||||||
| Number of shares | m | 86.56 | - | ||||||
| DPS (TTM paid) | $ | 0.00 | - |
Financial summary
Financials in USDTTM unavailable| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 0.54 | - | ||||||
| P/S LTM | x | 0.79 | - | ||||||
| P/FCF LTM | x | -0.82 | - | ||||||
| EV/EBITDA LTM | x | 19.64 | - | ||||||
| EV/Sales LTM | x | 0.62 | - | ||||||
| Earnings Yield LTM | % | -11.13% | - | ||||||
| FCF Yield | % | -121.62% | - | ||||||
| Quality | |||||||||
| ROE | % | -6.03% | - | ||||||
| ROIC | % | -7.22% | - | ||||||
| Operating margin | % | -13.78% | - | ||||||
| Gross margin | % | +88.00% | - | ||||||
| FCF/Sales | % | -95.93% | - | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +1556.8% | - | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | - | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | - | ||||||
| FCF/Debt | x | -2.40 | - | ||||||
| Net Debt/EBITDA | x | -5.30 | - | ||||||
| EBIT/Net interest | x | 0.00 | - | ||||||
| Net debt/market cap | % | 0.00% | - | ||||||
| Net debt/Equity | x | -0.74 | - | ||||||
| Gross debt/equity | x | 0.27 | - | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Century Therapeutics, Inc. is a biotechnology company dedicated to pioneering allogeneic cell therapies for a range of cancers, specifically solid tumors and hematological malignancies. The firm's foremost clinical program is CNTY-101, an allogeneic, induced pluripotent stem cell (iPSC)-derived CAR-iNK cell therapy. This therapy is specifically designed to target CD19 in patients with B-cell lymphoma that has relapsed or proven refractory to previous treatments. In addition to its lead candidate, the company's robust pipeline features several other therapeutic assets: CNTY-103: A CAR-iNK candidate aimed at CD133 + EGFR for recurrent glioblastoma. CNTY-102: A CAR-iT therapy targeting CD19 + CD79b, intended for relapsed or refractory B-cell lymphoma and other B-cell cancers. CNTY-104: A multi-specific CAR-iT or CAR-iNK candidate in development for acute myeloid leukemia. CNTY-106: Another multi-specific CAR-iNK or CAR-iT candidate for multiple myeloma. Established in 2018, Century Therapeutics, Inc. is based in Philadelphia, Pennsylvania.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Century Therapeutics, Inc. is a biotechnology company dedicated to pioneering allogeneic cell therapies for a range of cancers, specifically solid tumors and hematological malignancies. The firm's foremost clinical program is CNTY-101, an allogeneic, induced pluripotent stem cell (iPSC)-derived CAR-iNK cell therapy. This therapy is specifically designed to target CD19 in patients with B-cell lymphoma that has relapsed or proven refractory to previous treatments. In addition to its lead candidate, the company's robust pipeline features several other therapeutic assets: CNTY-103: A CAR-iNK candidate aimed at CD133 + EGFR for recurrent glioblastoma. CNTY-102: A CAR-iT therapy targeting CD19 + CD79b, intended for relapsed or refractory B-cell lymphoma and other B-cell cancers. CNTY-104: A multi-specific CAR-iT or CAR-iNK candidate in development for acute myeloid leukemia. CNTY-106: Another multi-specific CAR-iNK or CAR-iT candidate for multiple myeloma. Established in 2018, Century Therapeutics, Inc. is based in Philadelphia, Pennsylvania.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free